XENE

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Burnaby, Canada. The company specializes in developing neurological therapeutics by targeting ion channels, particularly potassium and sodium channels in the brain. Xenon has built its expertise around understanding the genetic basis of neurological disorders and translating these insights into targeted drug therapies. The company went public in 2014 and has since advanced multiple drug candidates through clinical trials, with its lead program <b>azetukalner</b> (XEN1101) currently in Phase 3 trials for epilepsy and depression.